Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · IEX Real-Time Price · USD
0.298
-0.036 (-10.78%)
At close: Jul 2, 2024, 4:00 PM
0.310
+0.012 (3.93%)
After-hours: Jul 2, 2024, 7:59 PM EDT
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
1.22M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 3.11M | -9.18M | -74.67% |
Dec 31, 2021 | 12.29M | 7.98M | 185.26% |
Dec 31, 2020 | 4.31M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 23.07M | 8.41M | 57.37% |
Dec 31, 2017 | 14.66M | 4.67M | 46.80% |
Dec 31, 2016 | 9.99M | -23.62M | -70.28% |
Dec 31, 2015 | 33.60M | -12.03M | -26.36% |
Dec 31, 2014 | 45.63M | 45.46M | 26,741.76% |
Dec 31, 2013 | 170.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPVO News
- 1 day ago - Aptevo Therapeutics Announces Closing of $2.75 Million Offering - Accesswire
- 4 days ago - Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 4 weeks ago - Aptevo Participating in the BIO International Convention - Accesswire
- 7 weeks ago - Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA - Accesswire
- 7 weeks ago - Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update - Accesswire
- 2 months ago - Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering - Accesswire
- 2 months ago - Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering - Accesswire
- 2 months ago - Aptevo Therapeutics Provides Pipeline Update - Accesswire